Insilico Medicine

Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.

Funding reportedLast round: Series D

Biotechnology ResearchBoston, United States

What company datasets say Insilico Medicine raised

Funding, as reported

Reported in all$401Min dollars

Rounds11

Last roundSeries D

Last round dateAug 2022

Investors listed33

From Insilico Medicine's own website and the SEC filings it signed: 3 on the team.

On the board, as filediJames Mellon

Investors who name them

Each firm lists Insilico Medicine on its own website. That is the firm's claim, a weaker thing than a round we watched, but a named source.

Startups like it

Add your raise, your deck and your story, and put Insilico Medicine in front of investors. Or tell us what we have wrong.